Zensun Got New Investment to Accelerate Phase III Clinical Trial of rhNRG-1
2010-02-12
In 2009, Zensun's anti-heart failure drug -- rhNRG-1 successfully finished Chinese phase II clinical trials and was approved to take US phase II clinical trials. At the same time, the proceeding drug development also achieved significant progress.
更多动态
Zensun is Collaborating with The Leibniz-Institut für Alternsforschung-Fritz-Lipmann-Institute.V. to Conduct a Preclinical Study of Neucardin® (recombinant human Neuregulin-1) for The Treatment of Schwannomas
ZENSUN ANNOUNCES THE INVESTIGATION OF NEUCARDIN FOR CHRONIC HEART FAILURE RECEIVES FAST TRACK DESIGNATION FROM THE US FDA
An International Multi-center Phase III Clinical Trial of Recombinant Human Neuregulin-1 is going to